 | • レポートコード：QYR2104Z1275 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、化学療法誘発性血小板減少症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（トロンボポエチン受容体作動薬、トロンボポエチン剤、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・化学療法誘発性血小板減少症治療の市場動向 ・企業の競争状況、市場シェア ・化学療法誘発性血小板減少症治療の種類別市場規模（トロンボポエチン受容体作動薬、トロンボポエチン剤、その他） ・化学療法誘発性血小板減少症治療の用途別市場規模（病院薬局、小売薬局、オンライン薬局） ・化学療法誘発性血小板減少症治療の北米市場規模2016-2027（アメリカ、カナダ） ・化学療法誘発性血小板減少症治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・化学療法誘発性血小板減少症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・化学療法誘発性血小板減少症治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・化学療法誘発性血小板減少症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Amgen Inc.、Novartis AG、Teva Pharmaceutical Industries Ltd、Mylan N.V.、Pfizer Inc、Janssen Global Services, LLC、Partner Therapeutics, Inc、Mission Pharmacal Company、Myelo Therapeutics GmbH、Jiangsu HengRui Medicine Co., Ltd、Dova Pharmaceuticals, Inc） ・結論 |
Cancer is a major chronic disease, which can be managed and treated by chemotherapy, radiation therapy, immunotherapy, hormone therapy, stem cell transplant, targeted therapy, and other therapies. Cancer can be treated by using one therapy or by using combination of therapies based on the stage, type of cancer, and other factors. Chemotherapy is the type of treatment, where the drugs are used to stop or slow the growth of cancer cells. Chemotherapy-induced thrombocytopenia is a serious complication in the chemotherapy-treated patients. This report focus on Chemotherapy-induced Thrombocytopenia Therapeutics market.
Market Analysis and Insights: Global Chemotherapy-induced Thrombocytopenia Therapeutics Market
The global Chemotherapy-induced Thrombocytopenia Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chemotherapy-induced Thrombocytopenia Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chemotherapy-induced Thrombocytopenia Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chemotherapy-induced Thrombocytopenia Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chemotherapy-induced Thrombocytopenia Therapeutics market.
Global Chemotherapy-induced Thrombocytopenia Therapeutics Scope and Market Size
Chemotherapy-induced Thrombocytopenia Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy-induced Thrombocytopenia Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Thrombopoietin Receptor Agonists
Thrombopoietic Agents
Others
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Amgen Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd
Mylan N.V.
Pfizer Inc
Janssen Global Services, LLC
Partner Therapeutics, Inc
Mission Pharmacal Company
Myelo Therapeutics GmbH
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Thrombopoietin Receptor Agonists
1.2.3 Thrombopoietic Agents
1.2.4 Others
1.3 Market by Application
1.3.1 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Perspective (2016-2027)
2.2 Chemotherapy-induced Thrombocytopenia Therapeutics Growth Trends by Regions
2.2.1 Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Chemotherapy-induced Thrombocytopenia Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Chemotherapy-induced Thrombocytopenia Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Chemotherapy-induced Thrombocytopenia Therapeutics Industry Dynamic
2.3.1 Chemotherapy-induced Thrombocytopenia Therapeutics Market Trends
2.3.2 Chemotherapy-induced Thrombocytopenia Therapeutics Market Drivers
2.3.3 Chemotherapy-induced Thrombocytopenia Therapeutics Market Challenges
2.3.4 Chemotherapy-induced Thrombocytopenia Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chemotherapy-induced Thrombocytopenia Therapeutics Players by Revenue
3.1.1 Global Top Chemotherapy-induced Thrombocytopenia Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Chemotherapy-induced Thrombocytopenia Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Chemotherapy-induced Thrombocytopenia Therapeutics Revenue
3.4 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Concentration Ratio
3.4.1 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chemotherapy-induced Thrombocytopenia Therapeutics Revenue in 2020
3.5 Chemotherapy-induced Thrombocytopenia Therapeutics Key Players Head office and Area Served
3.6 Key Players Chemotherapy-induced Thrombocytopenia Therapeutics Product Solution and Service
3.7 Date of Enter into Chemotherapy-induced Thrombocytopenia Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chemotherapy-induced Thrombocytopenia Therapeutics Breakdown Data by Type
4.1 Global Chemotherapy-induced Thrombocytopenia Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Chemotherapy-induced Thrombocytopenia Therapeutics Forecasted Market Size by Type (2022-2027)
5 Chemotherapy-induced Thrombocytopenia Therapeutics Breakdown Data by Application
5.1 Global Chemotherapy-induced Thrombocytopenia Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Chemotherapy-induced Thrombocytopenia Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size (2016-2027)
6.2 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type
6.2.1 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2027)
6.3 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application
6.3.1 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2027)
6.4 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country
6.4.1 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size (2016-2027)
7.2 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type
7.2.1 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2027)
7.3 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application
7.3.1 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2027)
7.4 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country
7.4.1 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type
8.2.1 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application
8.3.1 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Region
8.4.1 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size (2016-2027)
9.2 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type
9.2.1 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application
9.3.1 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country
9.4.1 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type
10.2.1 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application
10.3.1 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country
10.4.1 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Details
11.1.2 Amgen Inc. Business Overview
11.1.3 Amgen Inc. Chemotherapy-induced Thrombocytopenia Therapeutics Introduction
11.1.4 Amgen Inc. Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
11.1.5 Amgen Inc. Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Chemotherapy-induced Thrombocytopenia Therapeutics Introduction
11.2.4 Novartis AG Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
11.2.5 Novartis AG Recent Development
11.3 Teva Pharmaceutical Industries Ltd
11.3.1 Teva Pharmaceutical Industries Ltd Company Details
11.3.2 Teva Pharmaceutical Industries Ltd Business Overview
11.3.3 Teva Pharmaceutical Industries Ltd Chemotherapy-induced Thrombocytopenia Therapeutics Introduction
11.3.4 Teva Pharmaceutical Industries Ltd Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
11.3.5 Teva Pharmaceutical Industries Ltd Recent Development
11.4 Mylan N.V.
11.4.1 Mylan N.V. Company Details
11.4.2 Mylan N.V. Business Overview
11.4.3 Mylan N.V. Chemotherapy-induced Thrombocytopenia Therapeutics Introduction
11.4.4 Mylan N.V. Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
11.4.5 Mylan N.V. Recent Development
11.5 Pfizer Inc
11.5.1 Pfizer Inc Company Details
11.5.2 Pfizer Inc Business Overview
11.5.3 Pfizer Inc Chemotherapy-induced Thrombocytopenia Therapeutics Introduction
11.5.4 Pfizer Inc Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
11.5.5 Pfizer Inc Recent Development
11.6 Janssen Global Services, LLC
11.6.1 Janssen Global Services, LLC Company Details
11.6.2 Janssen Global Services, LLC Business Overview
11.6.3 Janssen Global Services, LLC Chemotherapy-induced Thrombocytopenia Therapeutics Introduction
11.6.4 Janssen Global Services, LLC Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
11.6.5 Janssen Global Services, LLC Recent Development
11.7 Partner Therapeutics, Inc
11.7.1 Partner Therapeutics, Inc Company Details
11.7.2 Partner Therapeutics, Inc Business Overview
11.7.3 Partner Therapeutics, Inc Chemotherapy-induced Thrombocytopenia Therapeutics Introduction
11.7.4 Partner Therapeutics, Inc Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
11.7.5 Partner Therapeutics, Inc Recent Development
11.8 Mission Pharmacal Company
11.8.1 Mission Pharmacal Company Company Details
11.8.2 Mission Pharmacal Company Business Overview
11.8.3 Mission Pharmacal Company Chemotherapy-induced Thrombocytopenia Therapeutics Introduction
11.8.4 Mission Pharmacal Company Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
11.8.5 Mission Pharmacal Company Recent Development
11.9 Myelo Therapeutics GmbH
11.9.1 Myelo Therapeutics GmbH Company Details
11.9.2 Myelo Therapeutics GmbH Business Overview
11.9.3 Myelo Therapeutics GmbH Chemotherapy-induced Thrombocytopenia Therapeutics Introduction
11.9.4 Myelo Therapeutics GmbH Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
11.9.5 Myelo Therapeutics GmbH Recent Development
11.10 Jiangsu HengRui Medicine Co., Ltd
11.10.1 Jiangsu HengRui Medicine Co., Ltd Company Details
11.10.2 Jiangsu HengRui Medicine Co., Ltd Business Overview
11.10.3 Jiangsu HengRui Medicine Co., Ltd Chemotherapy-induced Thrombocytopenia Therapeutics Introduction
11.10.4 Jiangsu HengRui Medicine Co., Ltd Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
11.10.5 Jiangsu HengRui Medicine Co., Ltd Recent Development
11.11 Dova Pharmaceuticals, Inc
11.11.1 Dova Pharmaceuticals, Inc Company Details
11.11.2 Dova Pharmaceuticals, Inc Business Overview
11.11.3 Dova Pharmaceuticals, Inc Chemotherapy-induced Thrombocytopenia Therapeutics Introduction
11.11.4 Dova Pharmaceuticals, Inc Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
11.11.5 Dova Pharmaceuticals, Inc Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Thrombopoietin Receptor Agonists
Table 3. Key Players of Thrombopoietic Agents
Table 4. Key Players of Others
Table 5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Chemotherapy-induced Thrombocytopenia Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Regions (2022-2027)
Table 11. Chemotherapy-induced Thrombocytopenia Therapeutics Market Trends
Table 12. Chemotherapy-induced Thrombocytopenia Therapeutics Market Drivers
Table 13. Chemotherapy-induced Thrombocytopenia Therapeutics Market Challenges
Table 14. Chemotherapy-induced Thrombocytopenia Therapeutics Market Restraints
Table 15. Global Chemotherapy-induced Thrombocytopenia Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Chemotherapy-induced Thrombocytopenia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics as of 2020)
Table 18. Ranking of Global Top Chemotherapy-induced Thrombocytopenia Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Chemotherapy-induced Thrombocytopenia Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Chemotherapy-induced Thrombocytopenia Therapeutics Product Solution and Service
Table 22. Date of Enter into Chemotherapy-induced Thrombocytopenia Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Chemotherapy-induced Thrombocytopenia Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Chemotherapy-induced Thrombocytopenia Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Chemotherapy-induced Thrombocytopenia Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Chemotherapy-induced Thrombocytopenia Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Chemotherapy-induced Thrombocytopenia Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Chemotherapy-induced Thrombocytopenia Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. Amgen Inc. Company Details
Table 63. Amgen Inc. Business Overview
Table 64. Amgen Inc. Chemotherapy-induced Thrombocytopenia Therapeutics Product
Table 65. Amgen Inc. Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021) & (US$ Million)
Table 66. Amgen Inc. Recent Development
Table 67. Novartis AG Company Details
Table 68. Novartis AG Business Overview
Table 69. Novartis AG Chemotherapy-induced Thrombocytopenia Therapeutics Product
Table 70. Novartis AG Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Novartis AG Recent Development
Table 72. Teva Pharmaceutical Industries Ltd Company Details
Table 73. Teva Pharmaceutical Industries Ltd Business Overview
Table 74. Teva Pharmaceutical Industries Ltd Chemotherapy-induced Thrombocytopenia Therapeutics Product
Table 75. Teva Pharmaceutical Industries Ltd Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Teva Pharmaceutical Industries Ltd Recent Development
Table 77. Mylan N.V. Company Details
Table 78. Mylan N.V. Business Overview
Table 79. Mylan N.V. Chemotherapy-induced Thrombocytopenia Therapeutics Product
Table 80. Mylan N.V. Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021) & (US$ Million)
Table 81. Mylan N.V. Recent Development
Table 82. Pfizer Inc Company Details
Table 83. Pfizer Inc Business Overview
Table 84. Pfizer Inc Chemotherapy-induced Thrombocytopenia Therapeutics Product
Table 85. Pfizer Inc Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021) & (US$ Million)
Table 86. Pfizer Inc Recent Development
Table 87. Janssen Global Services, LLC Company Details
Table 88. Janssen Global Services, LLC Business Overview
Table 89. Janssen Global Services, LLC Chemotherapy-induced Thrombocytopenia Therapeutics Product
Table 90. Janssen Global Services, LLC Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021) & (US$ Million)
Table 91. Janssen Global Services, LLC Recent Development
Table 92. Partner Therapeutics, Inc Company Details
Table 93. Partner Therapeutics, Inc Business Overview
Table 94. Partner Therapeutics, Inc Chemotherapy-induced Thrombocytopenia Therapeutics Product
Table 95. Partner Therapeutics, Inc Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021) & (US$ Million)
Table 96. Partner Therapeutics, Inc Recent Development
Table 97. Mission Pharmacal Company Company Details
Table 98. Mission Pharmacal Company Business Overview
Table 99. Mission Pharmacal Company Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Mission Pharmacal Company Recent Development
Table 101. Myelo Therapeutics GmbH Company Details
Table 102. Myelo Therapeutics GmbH Business Overview
Table 103. Myelo Therapeutics GmbH Chemotherapy-induced Thrombocytopenia Therapeutics Product
Table 104. Myelo Therapeutics GmbH Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021) & (US$ Million)
Table 105. Myelo Therapeutics GmbH Recent Development
Table 106. Jiangsu HengRui Medicine Co., Ltd Company Details
Table 107. Jiangsu HengRui Medicine Co., Ltd Business Overview
Table 108. Jiangsu HengRui Medicine Co., Ltd Chemotherapy-induced Thrombocytopenia Therapeutics Product
Table 109. Jiangsu HengRui Medicine Co., Ltd Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021) & (US$ Million)
Table 110. Jiangsu HengRui Medicine Co., Ltd Recent Development
Table 111. Dova Pharmaceuticals, Inc Company Details
Table 112. Dova Pharmaceuticals, Inc Business Overview
Table 113. Dova Pharmaceuticals, Inc Chemotherapy-induced Thrombocytopenia Therapeutics Product
Table 114. Dova Pharmaceuticals, Inc Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021) & (US$ Million)
Table 115. Dova Pharmaceuticals, Inc Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Thrombopoietin Receptor Agonists Features
Figure 3. Thrombopoietic Agents Features
Figure 4. Others Features
Figure 5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. Online Pharmacies Case Studies
Figure 9. Chemotherapy-induced Thrombocytopenia Therapeutics Report Years Considered
Figure 10. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Regions: 2020 VS 2027
Figure 13. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Regions (2022-2027)
Figure 14. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Players in 2020
Figure 15. Global Top Chemotherapy-induced Thrombocytopenia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy-induced Thrombocytopenia Therapeutics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Chemotherapy-induced Thrombocytopenia Therapeutics Revenue in 2020
Figure 17. Global Chemotherapy-induced Thrombocytopenia Therapeutics Revenue Market Share by Type (2016-2021)
Figure 18. Global Chemotherapy-induced Thrombocytopenia Therapeutics Revenue Market Share by Type (2022-2027)
Figure 19. North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Type (2016-2027)
Figure 21. North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Application (2016-2027)
Figure 22. North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Country (2016-2027)
Figure 23. United States Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Type (2016-2027)
Figure 27. Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Application (2016-2027)
Figure 28. Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Country (2016-2027)
Figure 29. Germany Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Region (2016-2027)
Figure 39. China Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Type (2016-2027)
Figure 47. Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Application (2016-2027)
Figure 48. Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Country (2016-2027)
Figure 49. Mexico Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Chemotherapy-induced Thrombocytopenia Therapeutics Market Share by Country (2016-2027)
Figure 55. Turkey Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Chemotherapy-induced Thrombocytopenia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Amgen Inc. Revenue Growth Rate in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
Figure 59. Novartis AG Revenue Growth Rate in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
Figure 60. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
Figure 61. Mylan N.V. Revenue Growth Rate in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
Figure 62. Pfizer Inc Revenue Growth Rate in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
Figure 63. Janssen Global Services, LLC Revenue Growth Rate in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
Figure 64. Partner Therapeutics, Inc Revenue Growth Rate in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
Figure 65. Mission Pharmacal Company Revenue Growth Rate in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
Figure 66. Myelo Therapeutics GmbH Revenue Growth Rate in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
Figure 67. Jiangsu HengRui Medicine Co., Ltd Revenue Growth Rate in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
Figure 68. Dova Pharmaceuticals, Inc Revenue Growth Rate in Chemotherapy-induced Thrombocytopenia Therapeutics Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
世界の化学療法誘発性悪心・嘔吐（CINV）市場規模・現状・予測（2021年-2027年） Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides…- 世界の化学療法誘発性貧血市場規模・現状・予測（2021年-2027年） Anaemia is a frequent complication of malignancy and is aggravated by chemotherapy. The key factor contributing to the growth of the global chemotherapy induced anemia market is the increase in the occurrence of cancer and anemia among geriatric patients. Market Analysis and Insights: Global Chemoth…
- 世界の血小板減少症管理市場規模・現状・予測（2021年-2027年） Thrombocytopenia is deficiency of platelets in the blood vessels, an auto immune hematological bleeding disorder. Due to high response rates from patients, increasing awareness and disposable income, the global thrombocytopenia management market is gradually increasing. Market Analysis and Insights:…
- 世界の化学療法薬誘発性肢端紅斑（手足症候群）治療市場規模・現状・予測（2021年-2027年） Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear afte…
- 世界の化学療法薬誘発性肢端紅斑（手足症候群）治療市場規模・現状・予測（2021年-2027年） Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear afte…